Distinct in vitro Complement Activation by Various Intravenous Iron Preparations

American Journal of Nephrology

Volumn 45, Issue 1, 2017, Pages 49-59

  Hempel, Julia Cordelia ^a   Poppelaars, Felix ^a   Gaya Da Costa, Mariana ^a   Franssen, Casper F M ^a   De Vlaam, Thomas P G ^a   Daha, Mohamed R ^a,b   Berger, Stefan P ^a   Seelen, Marc A J ^a   Gaillard, Carlo A J M ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Complement activation; Complement activation related pseudo allergy; Hypersensitivity reaction; Intravenous iron; Iron dextran; Iron sucrose

Indexed keywords

FERRIC CARBOXYMALTOSE; FERUMOXYTOL; IMMUNOGLOBULIN M; IRON; IRON DEXTRAN; LEPIRUDIN; LIPOPOLYSACCHARIDE; ANTIANEMIC AGENT; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3D; COMPLEMENT MEMBRANE ATTACK COMPLEX; DISACCHARIDE; FERRIC ION; IRON DERIVATIVE; IRON ISOMALTOSIDE 1000; IRON SACCHARATE; MAGNETITE; MALTOSE; MANNOSE BINDING LECTIN; PROPERDIN; SACCHARIC ACID;

ARTICLE; CLINICAL ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT CLASSICAL PATHWAY; COMPLEMENT LECTIN PATHWAY; CONTROLLED STUDY; HEMODIALYSIS PATIENT; HUMAN; HYPERSENSITIVITY; IN VITRO STUDY; NORMAL HUMAN; PRIORITY JOURNAL; ANALOGS AND DERIVATIVES; CHRONIC KIDNEY FAILURE; COMPLICATION; DRUG EFFECTS; HEMODIALYSIS; INTRAVENOUS DRUG ADMINISTRATION; IRON DEFICIENCY ANEMIA; METABOLISM;

ADMINISTRATION, INTRAVENOUS; ANEMIA, IRON-DEFICIENCY; COMPLEMENT ACTIVATION; COMPLEMENT C1Q; COMPLEMENT C3D; COMPLEMENT MEMBRANE ATTACK COMPLEX; DISACCHARIDES; FERRIC COMPOUNDS; FERROSOFERRIC OXIDE; GLUCARIC ACID; HEMATINICS; HUMANS; IN VITRO TECHNIQUES; IRON COMPOUNDS; IRON-DEXTRAN COMPLEX; KIDNEY FAILURE, CHRONIC; MALTOSE; MANNOSE-BINDING LECTIN; PROPERDIN; RENAL DIALYSIS;

EID: 85001073675     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000451060     Document Type: Article

References (24)

1. Saran R, Li Y, Robinson B, Ayanian J, Balkrishnan R, Bragg-Gresham J, Chen JT, Cope E, Gipson D, He K, Herman W, Heung M, Hirth RA, Jacobsen SS, Kalantar-Zadeh K, Kovesdy CP, Leichtman AB, Lu Y, Molnar MZ, Morgenstern H, Nallamothu B, O'Hare AM, Pisoni R, Plattner B, Port FK, Rao P, Rhee CM, Schaubel DE, Selewski DT, Shahinian V, Sim JJ, Song P, Streja E, Kurella Tamura M, Tentori F, Eggers PW, Agodoa LY, Abbott KC: US renal data system 2014 annual data report: epidemiology of kidney disease in the United States. Am J Kidney Dis 2015; 65(6 suppl 1):A7
2. European Medicines Agency: New Recommendations to Manage Risk of Allergic Reactions with Intravenous Iron-Containing Medicines, 2013
3. Wysowski DK, Swartz L, Borders-Hemphill BV, Goulding MR, Dormitzer C: Use of parenteral iron products and serious anaphylactic-type reactions. Am J Hematol 2010; 85: 650-654
4. Szebeni J, Fishbane S, Hedenus M, Howaldt S, Locatelli F, Patni S, Rampton D, Weiss G, Folkersen J: Hypersensitivity to intravenous iron: classification, terminology, mechanisms and management. Br J Pharmacol 2015; 172: 5025-5036
5. Szebeni J: Complement activation-related pseudoallergy caused by liposomes, micellar carriers of intravenous drugs, and radiocontrast agents. Crit Rev Ther Drug Carrier Syst 2001; 18: 567-606
6. Danielson BG: Structure, chemistry, and pharmacokinetics of intravenous iron agents. J Am Soc Nephrol 2004; 15(suppl 2):S93-S98
7. Walport MJ: Complement. First of two parts. N Engl J Med 2001; 344: 1058-1066
8. Roos A, Bouwman LH, Munoz J, Zuiverloon T, Faber-Krol MC, Fallaux-Houten FC, Klar-Mohamad N, Hack CE, Tilanus MG, Daha MR: Functional characterization of the lectin pathway of complement in human serum. Mol Immunol 2003; 39: 655-668
9. Mollnes TE, Brekke OL, Fung M, Fure H, Christiansen D, Bergseth G, Videm V, Lappegard KT, Kohl J, Lambris JD: Essential role of the C5a receptor in E coli-induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation. Blood 2002; 100: 1869-1877
10. Trouw LA, Seelen MA, Duijs JM, Benediktsson H, Van Kooten C, Daha MR: Glomerular deposition of C1q and anti-C1q antibodies in mice following injection of antimouse C1q antibodies. Clin Exp Immunol 2003;132:32-39
11. Poppelaars F, Gaya Costa M, Berger SP, Assa S, Meter-Arkema AH, Daha MR, et al: Strong predictive value of mannose-binding lectin levels for cardiovascular risk of hemodialysis patients. J Transl Med 2016;14:236
12. Poppelaars F, Gaya Costa M, Berger SP, Assa S, Meter-Arkema AH, Daha MR, et al: Erratum to: Strong predictive value of mannose-binding lectin levels for cardiovascular risk of hemodialysis patients. J Transl Med 2016;14:245
13. Roos A, Bouwman LH, Gijlswijk-Janssen DJ, Faber-Krol MC, Stahl GL, Daha MR: Human IgA activates the complement system via the mannan-binding lectin pathway. J Immunol 2001;167:2861-2868
14. DeAngelis RA, Reis ES, Ricklin D, Lambris JD: Targeted complement inhibition as a promising strategy for preventing inflammatory complications in hemodialysis. Immunobiology 2012; 217: 1097-1105
15. Auerbach M, Ballard H: Clinical use of intravenous iron: administration, efficacy, and safety. Hematology Am Soc Hematol Educ Program 2010; 2010: 338-347
16. Pai AB, Garba AO: Ferumoxytol: a silver lining in the treatment of anemia of chronic kidney disease or another dark cloud? J Blood Med 2012; 3: 77-85
17. Chaignon M, Chen WT, Tarazi RC, Bravo EL, Nakamoto S: Effect of hemodialysis on blood volume distribution and cardiac output. Hypertension 1981; 3: 327-332
18. Geisser P, Burckhardt S: The pharmacokinetics and pharmacodynamics of iron preparations. Pharmaceutics 2011; 3: 12-33
19. Michael B, Coyne DW, Fishbane S, Folkert V, Lynn R, Nissenson AR, Agarwal R, Eschbach JW, Fadem SZ, Trout JR, Strobos J, Warnock DG; Ferrlecit Publication Committee: Sodium ferric gluconate complex in hemodialysis patients: adverse reactions compared to placebo and iron dextran. Kidney Int 2002; 61: 1830-1839
20. Chanan-Khan A, Szebeni J, Savay S, Liebes L, Rafique NM, Alving CR, Muggia FM: Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions. Ann Oncol 2003; 14: 1430-1437
21. Banda NK, Mehta G, Chao Y, Wang G, Inturi S, Fossati-Jimack L, et al: Mechanisms of complement activation by dextran-coated superparamagnetic iron oxide (SPIO) nanoworms in mouse versus human serum. Part Fibre Toxicol 2014;11:64
22. Coyne DW, Adkinson NF, Nissenson AR, Fishbane S, Agarwal R, Eschbach JW, Michael B, Folkert V, Batlle D, Trout JR, Dahl N, Myirski P, Strobos J, Warnock DG; Ferlecit Investigators: Sodium ferric gluconate complex in hemodialysis patients. II. Adverse reactions in iron dextran-sensitive and dextran-tolerant patients. Kidney Int 2003; 63: 217-224
23. Wang C, Graham DJ, Kane RC, Xie D, Wernecke M, Levenson M, et al: Comparative risk of anaphylactic reactions associated with intravenous iron products. JAMA 2015;314:2062-2068
24. Szebeni J: Complement activation-related pseudoallergy: a stress reaction in blood triggered by nanomedicines and biologicals. Mol Immunol 2014;61:163-173